Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
November 9: Complimentary CuriLytics™ Lunch & Learn
WILMINGTON, Mass., Sept. 21, 2021 /PRNewswire/
CuriRx, Inc., a leading contract research (CRO) and product development organization, announced today the launch of their new CuriLytics™ platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services. Led by CuriRx’s team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics™ platform provides support to developers of complex biotherapeutics.
Learn more about CuriLytics™ here.
Read the full press release here.